[Small molecular agents against MERS-CoV infection].
Identifieur interne : 000C54 ( PubMed/Curation ); précédent : 000C53; suivant : 000C55[Small molecular agents against MERS-CoV infection].
Auteurs : Xiao-Yun Zeng ; Lu Lu ; Shi-Bo Jiang ; Shu-Wen LiuSource :
- Yao xue xue bao = Acta pharmaceutica Sinica [ 0513-4870 ] ; 2015.
Descripteurs français
- KwdFr :
- MESH :
- pharmacologie : Anticorps monoclonaux, Antiviraux.
- traitement médicamenteux : Infections à coronavirus.
- Conception de médicament, Coronavirus du syndrome respiratoire du Moyen-Orient, Humains.
English descriptors
- KwdEn :
- MESH :
- chemical , pharmacology : Antibodies, Monoclonal, Antiviral Agents.
- drug effects : Middle East Respiratory Syndrome Coronavirus.
- drug therapy : Coronavirus Infections.
- Drug Design, Humans.
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) has caused outbreaks of SARS-like disease with 35% case-fatality rate, mainly in the Middle East. A more severe outbreak of MERS occurred recently in the Republic of Korea, where 186 people contracted the infections, causing great concern worldwide. So far, there has been no clinically available drug for the treatment of MERS-CoV infection. The potential drugs against MERS-CoV mainly consist of monoclonal antibodies, peptides and small molecular agents. Small molecular agents have an advantage of easier synthesis, lower cost in production and relatively higher stability. There is better chance for those candidates to gain a quick development. This article reviews the progress of developing small molecular MERS-CoV agents.
PubMed: 27169271
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C54
Links to Exploration step
pubmed:27169271Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Small molecular agents against MERS-CoV infection].</title><author><name sortKey="Zeng, Xiao Yun" sort="Zeng, Xiao Yun" uniqKey="Zeng X" first="Xiao-Yun" last="Zeng">Xiao-Yun Zeng</name></author><author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name></author><author><name sortKey="Jiang, Shi Bo" sort="Jiang, Shi Bo" uniqKey="Jiang S" first="Shi-Bo" last="Jiang">Shi-Bo Jiang</name></author><author><name sortKey="Liu, Shu Wen" sort="Liu, Shu Wen" uniqKey="Liu S" first="Shu-Wen" last="Liu">Shu-Wen Liu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:27169271</idno><idno type="pmid">27169271</idno><idno type="wicri:Area/PubMed/Corpus">000C54</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C54</idno><idno type="wicri:Area/PubMed/Curation">000C54</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C54</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Small molecular agents against MERS-CoV infection].</title><author><name sortKey="Zeng, Xiao Yun" sort="Zeng, Xiao Yun" uniqKey="Zeng X" first="Xiao-Yun" last="Zeng">Xiao-Yun Zeng</name></author><author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name></author><author><name sortKey="Jiang, Shi Bo" sort="Jiang, Shi Bo" uniqKey="Jiang S" first="Shi-Bo" last="Jiang">Shi-Bo Jiang</name></author><author><name sortKey="Liu, Shu Wen" sort="Liu, Shu Wen" uniqKey="Liu S" first="Shu-Wen" last="Liu">Shu-Wen Liu</name></author></analytic><series><title level="j">Yao xue xue bao = Acta pharmaceutica Sinica</title><idno type="ISSN">0513-4870</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (pharmacology)</term><term>Antiviral Agents (pharmacology)</term><term>Coronavirus Infections (drug therapy)</term><term>Drug Design</term><term>Humans</term><term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux (pharmacologie)</term><term>Antiviraux (pharmacologie)</term><term>Conception de médicament</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term><term>Humains</term><term>Infections à coronavirus (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Design</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Conception de médicament</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Middle East respiratory syndrome coronavirus (MERS-CoV) has caused outbreaks of SARS-like disease with 35% case-fatality rate, mainly in the Middle East. A more severe outbreak of MERS occurred recently in the Republic of Korea, where 186 people contracted the infections, causing great concern worldwide. So far, there has been no clinically available drug for the treatment of MERS-CoV infection. The potential drugs against MERS-CoV mainly consist of monoclonal antibodies, peptides and small molecular agents. Small molecular agents have an advantage of easier synthesis, lower cost in production and relatively higher stability. There is better chance for those candidates to gain a quick development. This article reviews the progress of developing small molecular MERS-CoV agents.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27169271</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0513-4870</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>12</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Yao xue xue bao = Acta pharmaceutica Sinica</Title><ISOAbbreviation>Yao Xue Xue Bao</ISOAbbreviation></Journal><ArticleTitle>[Small molecular agents against MERS-CoV infection].</ArticleTitle><Pagination><MedlinePgn>1520-6</MedlinePgn></Pagination><Abstract><AbstractText>Middle East respiratory syndrome coronavirus (MERS-CoV) has caused outbreaks of SARS-like disease with 35% case-fatality rate, mainly in the Middle East. A more severe outbreak of MERS occurred recently in the Republic of Korea, where 186 people contracted the infections, causing great concern worldwide. So far, there has been no clinically available drug for the treatment of MERS-CoV infection. The potential drugs against MERS-CoV mainly consist of monoclonal antibodies, peptides and small molecular agents. Small molecular agents have an advantage of easier synthesis, lower cost in production and relatively higher stability. There is better chance for those candidates to gain a quick development. This article reviews the progress of developing small molecular MERS-CoV agents.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Xiao-yun</ForeName><Initials>XY</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Lu</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Shi-bo</ForeName><Initials>SB</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shu-wen</ForeName><Initials>SW</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Yao Xue Xue Bao</MedlineTA><NlmUniqueID>21710340R</NlmUniqueID><ISSNLinking>0513-4870</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27169271</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C54 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000C54 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:27169271
|texte= [Small molecular agents against MERS-CoV infection].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:27169271" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |